{"groups":[{"description":"Enrolled patients will be treated with nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks).\n\nNivolumab: nivolumab 3 mg/kg every 2 weeks\n\nIpilimumab: ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks)","id":"FG000","title":"R/M Adenoid Cystic Carcinoma (ACC)"},{"description":"Enrolled patients will be treated with nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks).\n\nNivolumab: nivolumab 3 mg/kg every 2 weeks\n\nIpilimumab: ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks)","id":"FG001","title":"R/M SGC of Any Histology, Except ACC (Non ACC)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"32"},{"groupId":"FG001","numSubjects":"32"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"32"},{"groupId":"FG001","numSubjects":"32"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}